#India #Bengaluru #Drug Development #Bristol Myers Squibb #Syngene International

Syngene International and Bristol Myers Squibb Extend Their Research Collaboration

In a significant development for the pharmaceutical industry, Syngene International, a prominent contract research, development, and manufacturing organization (CRDMO), has renewed its long-standing collaboration with Bristol Myers Squibb (BMS). This strategic partnership has been extended until 2035, enhancing the capabilities and scope of drug development services offered by Syngene.

Details of the Extended Collaboration

The renewed agreement signifies a pivotal step in the evolution of their collaboration, which has lasted over 25 years. The extended partnership envisions an integrated approach across various phases of drug development. This includes early-stage drug discovery encompassing chemistry, biology, drug metabolism, and pharmacokinetics, as well as translational sciences, pharmaceutical development, clinical trials, and data services. This holistic strategy aims to streamline the transition from research to market.

Peter Bains, CEO of Syngene International, emphasized the foundation of this partnership lies in scientific excellence and operational reliability. He stated, "The extension of our collaboration allows us to align our goals for the upcoming decade, focusing on developing new capabilities and infrastructures that will enhance both companies' strategic value. Together, we look forward to advancing BMS's discovery and development programs that have the potential to revolutionize patient outcomes globally."

Payal Sheth, Senior Vice President of Therapeutic Discovery at Bristol Myers Squibb, echoed this sentiment by underscoring the importance of patient-centric approaches in their operations. She highlighted that the partnership has been vital in propelling BMS's scientific ambitions, with the expanded collaboration underscoring their commitment to innovative science. According to Sheth, the integration of research, development, and manufacturing capabilities is crucial in delivering transformative therapies to patients worldwide.

Historical Context and Achievements

Since the inception of their collaboration in 1998, a landmark achievement was the establishment of the Bristol Myers Squibb Research and Development Center within Syngene, which became operational in 2009. This center has played a pivotal role in advancing research capabilities, serving as a strategic hub for integrated services such as target identification, candidate discovery, pharmaceutical development, and clinical biomarker science.

Today, this facility is home to approximately 700 Syngene scientists who function as an extension of BMS's global research organization. Their contributions span across various therapeutic areas, including cardiovascular health, fibrosis, immunology, and oncology. By fast-tracking the progression of new compounds from discovery to early human trials, the center has significantly reduced development timelines and costs for Bristol Myers Squibb.

Forward-Looking Strategies

The expansion of this partnership is not merely an extension in years; it is a foresight into a decade of mutual growth and innovation. Both companies are well equipped to leverage their combined strengths to foster groundbreaking therapies that can significantly enhance patient lives. The emphasis remains on building upon their existing successes while venturing into new scientific territories that promise to redefine treatment paradigms.

Syngene International has established itself as a key player in the global pharmaceutical landscape, providing an array of integrated research, development, and manufacturing services for prominent sectors such as pharmaceutical, biotechnology, and consumer healthcare. With more than 8,200 team members, including over 5,600 scientists, Syngene is dedicated to delivering scientific excellence and expedited manufacturing solutions. Their sophisticated service offerings are designed to meet the evolving demands of drug development in a timely and cost-effective manner.

The commitment to advancing science and enhancing drug availability continues to be at the forefront of both Syngene and Bristol Myers Squibb’s ethos. As they embark on this new chapter together, the industry watches closely to see how this partnership will push the boundaries of medical science and improve patient care.

Conclusion

With this extended collaboration, both Syngene International and Bristol Myers Squibb demonstrate a robust commitment to not just advancing their individual missions but also to revolutionizing patient care through innovative solutions. The future holds exciting possibilities as they harness their resources and expertise in the pursuit of medical breakthroughs.